Anca Vasculitis

Reduced glucocorticoids alongside rituximab are noninferior to a regimen of high-dose glucocorticoids plus rituximab for remission induction at 6 months in patients with new ANCA-associated vasculitis, according to data published in JAMA.

Treatment with a fixed interval of either 500 mg or 1,000 mg rituximab for at least 2 years is a “reasonable option” for patients with anti-neutrophil cytoplasmic autoantibody vasculitis upon achieving remission, according to a presenter here.

The FDA Arthritis Advisory Committee recently voted 10-8 that the safety and risk-benefit profiles for 30 mg dose of avacopan were sufficient to support its approval for the treatment of adult patients with ANCA-associated vasculitis.

Despite an ever-growing array of therapeutic options, patients with antineutrophil cytoplasmic antibody-associated vasculitis often fail to achieve remission, according to a speaker at the ACR State-of-the-Art Clinical Symposium.

The final episode summarizes the human data on complement in ANCA vasculitis, with a quick discussion of the trials of C5a receptor antagonism.

Avacopan is superior to prednisone taper in preventing relapse in patients with antineutrophil cytoplasmic antibody-associated vasculitis at 1 year, and is at least as effective as steroids in controlling the disease at 6 months, according to data.

Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic autoantibody vasculitis, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

This episode walks us through the initial research that paved the way for a game changing therapeutic in ANCA vasculitis, as well as the story of how host Adam J. Brown, MD, finally learned how to spell complement.

The completion of the Endocarditis for the Rheumatologist trilogy! This episode focuses on the glomerulonephritis of endocarditis as well as the immunologic abnormalities you can see on labs.

In this video, Fahmeedah Kamal, MD, highlights challenges in vasculitis and what research can do to address them.